Efficacy of CMC-Na oral film combined with rb-bFGF gel in the treatment of radiation-induced oral mucositis in patients with head and neck cancer

doi:10.19439/j.sjos.2025.05.012

Abstract

Abstract: PURPOSE: To investigate the therapeutic effect of sodium carboxymethyl cellulose (CMC-Na) oral film combined with recombinant bovine basic fibroblast growth factor (rb-bFGF) gel on radiation-induced oral mucositis (RIOM) in patients with head and neck cancer(HNC). METHODS: A total of 31 HNC patients with RIOM after radiotherapy in Lishui People's Hospital from June 2022 to January 2024 were randomly divided into three groups: group A (n=11), group B (n=11), and group C (n=9). Group A received CMC-Na oral film + rb-bFGF gel, group B received rb-bFGF gel alone, and group C received cetylpyridinium chloride mouthwash (control). On days 0, 5, 10 and 15, the OM grade and pain scores of each patient were evaluated using oral mucositis (OM) grading scale and numeric rating scale (NRS). The quality of life of patients before and after treatment was evaluated by using Oropharyngeal Mucositis Quality of Life (OMQoL) scale. RESULTS: After treatment in both group A and B, the pain scores and OM grades were significantly lower than those before treatment (P<0.05), while there was no significant difference in group C before and after treatment (P>0.05). Comparative analysis across time points revealed that pain scores in group A were significantly lower than those in group B on day 5 and 10 (P<0.05), with no significant difference on day 15(P>0.05). OM grades in group A were significantly lower than those in group B only on day 10 (P<0.05). Quality of life improved significantly in groups A and B(P<0.05), with greater improvement in group A, while no significant improvement was observed in group C(P>0.05). CONCLUSIONS: CMC-Na oral film combined with rb-bFGF gel demonstrates superior efficacy in treating RIOM in HNC patients compared to rb-bFGF gel alone, while cetylpyridinium chloride mouthwash shows no significant therapeutic effect.

Key words: Radiation-induced oral mucositis, Sodium carboxymethyl cellulose, Recombinant bovine basic fibroblast growth factor, Drug delivery systems

CLC Number:

R781.5

Xie Zeneng, Jiang Yinhua. Efficacy of CMC-Na oral film combined with rb-bFGF gel in the treatment of radiation-induced oral mucositis in patients with head and neck cancer[J]. Shanghai Journal of Stomatology, 2025, 34(5): 518-523.

References

[1] Sonis ST.Oral mucositis in head and neck cancer: risk, biology, and management[J]. Am Soc Clin Oncol Educ Book, 2013, 33(1): e236-e240.
[2] Elting LS, Cooksley CD, Chambers MS, et al.Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies[J]. Int J Radiat Oncol Biol Phys, 2007, 68(4): 1110-1120.
[3] Maria OM, Eliopoulos N, Muanza T.Radiation-induced oral mucositis[J]. Front Oncol, 2017, 7: 89.
[4] Elad S, Yarom N, Zadik Y, et al.The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies[J]. CA Cancer J Clin, 2022, 72(1): 57-77.
[5] Elad S, Cheng KKF, Lalla RV, et al.MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy[J]. Cancer, 2020, 126(19): 4423-4431.
[6] Yarom N, Hovan A, Bossi P, et al.Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents[J]. Support Care Cancer, 2020, 28(5): 2457-2472.
[7] Cheng KKF, Lee J, Leung SF, et al.Use of Rasch analysis in the evaluation of the Oropharyngeal Mucositis Quality Of Life Scale[J]. Nurs Res, 2011, 60(4):256-263.
[8] Logan RM, Al-Azri AR, Bossi P, et al.Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines[J]. Support Care Cancer, 2020, 28(5): 2485-2498.
[9] El Agha E, Kosanovic D, Schermuly RT, et al.Role of fibroblast growth factors in organ regeneration and repair[J]. Semin Cell Dev Biol, 2016, 53: 76-84.
[10] Coutsouvelis J, Corallo C, Spencer A, et al.A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy[J]. Crit Rev Oncol Hematol, 2022, 172: 103606.
[11] Le QT, Kim HE, Schneider CJ, et al.Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study[J]. J Clin Oncol, 2011, 29(20): 2808-2814.
[12] Spielberger R, Stiff P, Bensinger W, et al.Palifermin for oral mucositis after intensive therapy for hematologic cancers[J]. N Engl J Med, 2004, 351(25): 2590-2598.
[13] Suharyani I, Fouad Abdelwahab Mohammed A, Muchtaridi M, et al. Evolution of drug delivery systems for recurrent aphthous stomatitis[J]. Drug Des Devel Ther, 2021, 15: 4071-4089.
[14] 许翔, 陈旭, 柯月娇, 等. 基于层次分析法和正交设计优选长效缓释口腔溃疡膜的制备工艺研究[J]. 药学实践与服务,2023, 41(8): 501-508.
[15] Javanbakht S, Shaabani A.Carboxymethyl cellulose-based oral delivery systems[J]. Int J Biol Macromol, 2019, 133: 21-29.
[16] El-Sayed S, Nabid A, Shelley W, et al.Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase Ⅲ, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system[J]. J Clin Oncol, 2002, 20(19): 3956-3963.
[17] Saunders DP, Rouleau T, Cheng K, et al.Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines[J]. Support Care Cancer, 2020, 28(5): 2473-2484.
[18] Hu X, Yan Y, Liu W, et al.Advances and perspectives on pharmacological activities and mechanisms of the monoterpene borneol[J]. Phytomedicine, 2024, 132: 155848.